No broad new standard for treating acne during pregnancy appeared in August 2026. The documented changes were a June FDA isotretinoin label revision and recent reviews that refine the evidence without changing core safety advice. The practical message remains clear: several topical ingredients may be options, while oral isotretinoin and other high-risk medicines must be avoided. Newer ideas remain too weakly studied for self-directed use during pregnancy.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What actually changed in 2026?
- Which over-the-counter ingredients are options?
- Which acne medicines should be stopped or avoided?
- Is azelaic acid the best-supported topical option?
- What should readers watch next?
What actually changed in 2026?
The FDA revised the Absorica label in June, but it did not relax the pregnancy warning. Isotretinoin remains contraindicated because exposure at any amount can cause life-threatening birth defects, and access remains restricted through iPLEDGE REMS, a safety program controlling how the drug is prescribed and dispensed. The FDA's revised label confirms these requirements.
Two reviews also appeared in 2026. A July review examined myo-inositol as a possible adjunct, while a February review emphasized the shortage of pregnancy-specific drug research. Neither established a new first-line acne treatment.
Which over-the-counter ingredients are options?
ACOG says pregnant patients may use topical benzoyl peroxide, azelaic acid, salicylic acid, and glycolic acid. Its current pregnancy skin-care guidance advises discussing products containing other active ingredients with an obstetric clinician.
That does not make every product interchangeable. Concentration, application area, frequency, and combinations can differ, so review the full ingredient list rather than relying on the front label. A practical check before starting or continuing a product:.
- Identify every active ingredient.
- Compare the list with ACOG's stated options.
- Ask an obstetric clinician about unfamiliar actives or combination formulas.
- Use benzoyl peroxide only in limited amounts and with clinician input, following the AAD's cautious guidance.
Which acne medicines should be stopped or avoided?
Pregnant patients should not use isotretinoin, tazarotene, or spironolactone, according to the American Academy of Dermatology. Most experts also advise stopping adapalene and tretinoin. This matters because adapalene and tretinoin are common topical retinoids, while tazarotene is another medicine in the same drug family.
A topical product should not be assumed safe merely because it is applied to the skin. Anyone who becomes pregnant while taking isotretinoin should stop taking it and contact the prescribing clinician immediately. Do not replace it with another retinoid without medical review.
Is azelaic acid the best-supported topical option?
Azelaic acid has encouraging evidence, but the evidence is not definitive. The AAD considers it pregnancy-compatible based on animal data, reflecting the lack of drug trials involving pregnant people. A 2025 retrospective study followed 197 pregnant acne patients.
The 26 patients using 20% azelaic acid had greater lesion and investigator-grade improvement than those using topical erythromycin or clindamycin, according to the Journal of Cosmetic Dermatology study. However, the researchers did not randomly assign treatments, and the azelaic-acid group was small. The findings support discussing azelaic acid with a clinician, not treating it as proven superior for every pregnant patient.
What should readers watch next?
Myo-inositol may be worth studying, particularly for pregnant patients with polycystic ovary syndrome or metabolic or hormone-related features. Yet the July 2026 review found limited pregnancy-specific acne evidence and limited evidence for topical acne use. The larger issue is the evidence gap.
A February 2026 university-led review found that pregnant and lactating people remain excluded from randomized trials, leaving important questions about drug absorption and fetal risk unanswered. Watch for pregnancy-specific comparative studies and stronger safety data. Until those arrive, do not add myo-inositol or another newer treatment solely because early research describes it as promising.